Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial

Bibliographic Details
Main Authors:	Jenkinson, S, Koo, K, Goulden, N, Vora, A, Mitchell, C, Wade, R, Richards, S, Hancock, J, Moorman, A, Linch, D, Gale, R
Format:	Conference item
Published:	2012

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
by: Jenkinson, S, et al.
Published: (2013)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
by: Vora, A, et al.
Published: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
by: Vora, A, et al.
Published: (2008)

Outcome of Thrombosis in UKALL 2003-Anticoagulation and Re-Exposure to Aspariginase Is Feasible and Safe.
by: Qureshi, A, et al.
Published: (2008)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
by: Moorman, A, et al.
Published: (2013)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
by: Patrick, K, et al.
Published: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
by: Patrick, K, et al.
Published: (2014)

Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003
by: Patrick, K, et al.
Published: (2013)

Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
by: Qureshi, A, et al.
Published: (2010)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
by: Vora, A, et al.
Published: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
by: Vora, A, et al.
Published: (2013)

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties.
by: Chessells, J, et al.
Published: (1998)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
by: O'Connor, D, et al.
Published: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
by: Vora, A, et al.
Published: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
by: Vora, A, et al.
Published: (2014)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
by: Cutting, R, et al.
Published: (2008)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
by: Cutting, R, et al.
Published: (2009)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
by: Samarasinghe, S, et al.
Published: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
by: Samarasinghe, S, et al.
Published: (2013)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
by: Vora, A, et al.
Published: (2010)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
by: Eiser, C, et al.
Published: (2012)

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials.
by: Chessells, J, et al.
Published: (1995)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
by: Vora, A, et al.
Published: (2012)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
by: O'Connor, D, et al.
Published: (2014)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
by: Secker-Walker, L, et al.
Published: (1997)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
by: Harrison, G, et al.
Published: (2000)

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.
by: Wheeler, K, et al.
Published: (1996)

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
by: Sive, J, et al.
Published: (2012)

Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X.
by: Chessells, J, et al.
Published: (1992)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
by: Hann, I, et al.
Published: (2000)

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience
by: Wheeler, K, et al.
Published: (1998)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial
by: Harrison, G, et al.
Published: (2000)

Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study
by: Eiser, C, et al.
Published: (2017)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
by: Mansour, MR, et al.
Published: (2009)

P343: GENOMIC CHARACTERISATION OF B-OTHER ALL IN UKALL2003 PATIENTS BY NEXT GENERATION SEQUENCING
by: C. Schwab, et al.
Published: (2022-06-01)

Intramuscular PEG-Asparaginase At 1000 U/m(2) Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol
by: Fong, C, et al.
Published: (2011)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
by: Fielding, A, et al.
Published: (2007)

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
by: Chessels, J, et al.
Published: (1997)

Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial

Similar Items

Similar Items